Valuation: Assembly Biosciences, Inc.

Market Cap 516M 454M 422M 388M 727M 49.97B 740M 5.04B 1.97B 24.38B 1.94B 1.9B 84.57B P/E 2026 *
-24x
P/E 2027 * -9.08x
Enterprise Value 516M 454M 422M 388M 727M 49.97B 740M 5.04B 1.97B 24.38B 1.94B 1.9B 84.57B EV / Sales 2026 *
11.3x
EV / Sales 2027 * 16x
Free-Float
71.58%
Yield 2026 *
-
Yield 2027 * -
1 day-3.15%
1 week-2.40%
Current month-8.22%
1 month-5.90%
3 months-10.98%
6 months-9.96%
Current year-25.85%
1 week 24.87
Extreme 24.87
28.15
1 month 24.01
Extreme 24.01
29.94
Current year 21.8
Extreme 21.795
34.68
1 year 16.9
Extreme 16.9
39.7
3 years 7.69
Extreme 7.692
39.7
5 years 7.69
Extreme 7.692
47.28
10 years 7.69
Extreme 7.692
808.32
Manager TitleAgeSince
Chief Executive Officer 50 01/01/2023
Director of Finance/CFO - 05/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 04/06/2026
Director/Board Member 61 14/12/2017
Director/Board Member 68 06/08/2019
Date Insider Type Main position Quantity % Market Cap.
6/17/26 A Sell

Chief Financial Officer

-29 0.0002%
6/4/26 A Free

Director

8,000 0.0514%
6/4/26 A Free

Director

8,000 0.0514%
Change 5-day change 1-year change 3-year change Capi.($)
-3.15%-2.40%+37.59%+91.06% 516M
+1.08%-6.74%-2.31%+10.45% 46.06B
+3.13%+5.34%+402.93%+627.64% 38.91B
+2.14%+2.95%+10.83%+67.37% 35.57B
+4.43%-1.51%+6.73%-9.13% 33.13B
+1.23%-1.99%-0.05%+30.76% 26.42B
+0.29%-2.75% - - 16.61B
+14.71%+12.62%+38.50%+145.33% 15.08B
-6.32%-4.59%+4.36%+8.22% 14.08B
+1.82%+0.19%+1.45%-29.80% 12.81B
Average +2.02%-2.02%+55.56%+104.65% 23.92B
Weighted average by Cap. +2.58%-2.47%+75.75%+133.81%

Financials

2026 *2027 *
Net sales 45.47M 39.99M 37.15M 34.17M 64.08M 4.4B 65.23M 444M 173M 2.15B 171M 167M 7.45B 32.25M 28.36M 26.35M 24.23M 45.45M 3.12B 46.26M 315M 123M 1.52B 121M 118M 5.28B
Net income -20.46M -18M -16.72M -15.38M -28.84M -1.98B -29.35M -200M -77.98M -967M -76.82M -75.16M -3.35B -56.38M -49.58M -46.06M -42.37M -79.45M -5.46B -80.87M -551M -215M -2.66B -212M -207M -9.24B
Net Debt - -
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
23/07/26 $25.22 -3.15% 191,255
22/07/26 $26.04 -1.62% 128,331
21/07/26 $26.47 +5.63% 112,042
20/07/26 $25.06 -6.53% 112,884
17/07/26 $26.81 +3.75% 312,835
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
26.04USD
Average target price
50.00USD
Spread / Average Target
+92.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock